CBD and Plaquenil: what years on hydroxychloroquine taught me
Bottom line. I took Plaquenil for years as part of my RA stack. When I added CBD, the interaction I had to think through wasn't dramatic, but it was real. Hydroxychloroquine (Plaquenil) is metabolized by CYP2D6 and CYP3A4, both inhibited by CBD. CBD may slow HCQ clearance and raise plasma levels. The primary long-term concern is retinopathy: elevated HCQ plasma levels over time are functionally similar to taking a higher daily dose, which is the main driver of HCQ's cumulative retinopathy risk. The ACR already recommends annual ophthalmology monitoring after 5 years on HCQ, that monitoring becomes more important, not less, when you add a CYP inhibitor. Talk to your rheumatologist and keep those eye appointments.
Key takeaways
- HCQ uses CYP2D6 and CYP3A4; CBD inhibits both, so CBD may slow HCQ clearance and raise plasma levels.
- Raised HCQ plasma levels over time are functionally equivalent to a higher daily dose, which increases cumulative retinopathy risk.
- This is a slow-developing concern: HCQ has a 40–60 day half-life, so effects accumulate over months, not days.
- If you're on HCQ plus MTX, you have two distinct CYP interaction concerns, both worth covering with your rheumatologist.
- Annual ophthalmology screening after 5 years on HCQ is ACR-recommended regardless; adding a CYP inhibitor makes that monitoring more important, not less.
The pharmacokinetic mechanism
Hydroxychloroquine is metabolized by CYP2D6 (primary) and CYP3A4 (secondary) to its active metabolite desethylhydroxychloroquine. Bansal 2023's n=18 RCT confirmed CBD raises CYP2D6 and CYP3A4 substrate plasma exposure significantly at research doses. Stöllberger 2023's review of 403 CYP-substrate drugs identifies hydroxychloroquine as having dual-pathway overlap with CBD's inhibition profile.
The clinical concern is cumulative rather than acute: unlike warfarin (where INR changes can be detected quickly), HCQ plasma level changes accumulate slowly because HCQ has an extraordinarily long half-life (40–60 days). If CBD chronically raises HCQ levels, the effect builds gradually over months.
The retinopathy connection
The primary safety concern with long-term HCQ use is retinopathy — damage to the retina that can cause irreversible vision loss. Retinopathy risk is dose-dependent and cumulative: above 5.0 mg/kg/day and after 5+ years of use, risk increases substantially. If CBD raises HCQ plasma levels chronically, it's pharmacokinetically equivalent to taking a higher daily dose — which shifts the retinopathy risk curve.
The American College of Rheumatology already recommends annual ophthalmologic screening after 5 years on HCQ. This monitoring is the right safety net — and is even more important if you're adding a CYP inhibitor like CBD. If you notice sudden vision changes, blind spots, or flashing lights while on HCQ, call 911 (or your local emergency number) immediately or go to the nearest emergency room — do not wait to contact your prescriber.
The autoimmune stack concern
Many patients with RA or lupus take HCQ alongside methotrexate, biologics, or prednisone. Each of those medications has its own CBD interaction profile:
- Methotrexate - CYP3A4 + UGT pathways
- Biologics - not CYP-mediated; lower pharmacokinetic concern
- Prednisone - CYP3A4 substrate
The conversation with your rheumatologist should cover your full medication list, not just plaquenil in isolation.
What this means for you
- Tell your rheumatologist before starting CBD. Mention the HCQ dose, how long you've been on it, and whether your cumulative dose already puts you in the higher-risk retinopathy range.
- Continue ophthalmology monitoring. ACR recommends annual eye exams after year 5. This is already standard of care and is the appropriate safety net here.
- Topical CBD carries the lowest systemic risk. The NANO roll-on has minimal systemic absorption. For localized joint use, it's the lowest-CYP-exposure format.
- The slow HCQ half-life means changes take time. Unlike warfarin (where you can check INR in days), HCQ accumulates slowly. Plasma level changes from CBD inhibition would emerge over weeks to months — underscoring the value of ongoing monitoring rather than a one-time check.
Frequently asked questions
Can I take CBD if I'm on Plaquenil for RA or lupus?
I took Plaquenil for years and added CBD during that time. The honest answer: the interaction is real and worth knowing about, but it's manageable with awareness. HCQ uses CYP2D6 and CYP3A4, both inhibited by CBD, so CBD may slow HCQ clearance. The specific concern is retinopathy, elevated HCQ levels over time compound the cumulative risk. Tell your rheumatologist. Keep your ophthalmology appointments, they're already required, and they're the right safety net here.
Does raised HCQ plasma level increase retinopathy risk?
Yes, and this is the specific thing to understand. HCQ retinopathy risk is cumulative and dose-dependent. If CBD chronically raises HCQ plasma levels, it's pharmacokinetically equivalent to taking a higher daily dose, which shifts the retinopathy risk curve. This is a slow-developing concern: HCQ has a 40–60 day half-life, so changes accumulate over months, not days. The ACR already recommends annual ophthalmologic screening after 5 years on HCQ regardless of CBD. Don't skip those appointments.
I'm on both Plaquenil and methotrexate. What should I know about CBD?
This was my actual situation for a long time. You have two separate pharmacokinetic concerns: CYP2D6 and CYP3A4 overlap with HCQ, and CYP3A4 overlap with MTX. Neither one is a reason to avoid CBD categorically, but both warrant a conversation with your rheumatologist covering your full medication list. See the methotrexate page for the MTX-specific details.
References
- Bansal S et al. (2023). Cannabidiol effects on the pharmacokinetics of substrates of cytochrome P450 enzymes. PMID 37313955
- Stöllberger C, Finsterer J. (2023). Interactions between cannabidiol and commonly used prescription drugs. PMID 37541924
- Nachnani R et al. (2024). Cannabidiol-prescription drug interactions: a systematic review. PMID 38868665